SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 4,665 shares of the firm’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $23.32, for a total transaction of $108,787.80. Following the completion of the sale, the insider owned 206,585 shares in the company, valued at $4,817,562.20. This represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anshul Maheshwari also recently made the following trade(s):
- On Tuesday, November 17th, Anshul Maheshwari sold 1,715 shares of SiBone stock. The stock was sold at an average price of $23.19, for a total transaction of $39,770.85.
- On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The stock was sold at an average price of $25.00, for a total transaction of $81,175.00.
- On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00.
- On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total transaction of $33,754.50.
- On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total transaction of $60,321.24.
- On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total transaction of $233,999.96.
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $224,784.56.
SiBone Price Performance
NASDAQ SIBN opened at $23.75 on Friday. The firm’s fifty day simple moving average is $20.78 and its two-hundred day simple moving average is $16.92. The firm has a market capitalization of $1.07 billion, a P/E ratio of -76.61 and a beta of 0.64. The company has a current ratio of 7.58, a quick ratio of 6.15 and a debt-to-equity ratio of 0.19. SiBone has a 12-month low of $11.48 and a 12-month high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. Analysts forecast that SiBone will post -0.34 EPS for the current fiscal year.
Hedge Funds Weigh In On SiBone
Hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC raised its stake in SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after acquiring an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC grew its stake in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY increased its holdings in shares of SiBone by 113.3% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after purchasing an additional 598,300 shares during the period. Renaissance Technologies LLC increased its holdings in shares of SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after purchasing an additional 238,219 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after purchasing an additional 182,465 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the company. UBS Group raised their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Citigroup restated a “market outperform” rating on shares of SiBone in a report on Tuesday, November 3rd. Truist Financial upped their price objective on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. TD Cowen increased their price objective on shares of SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.
View Our Latest Analysis on SIBN
Latest SiBone News
Here’s some of the latest news about SIBN:
- Neutral Sentiment: SI-BONE will participate in the Piper Sandler Healthcare Conference on December 1, where management is scheduled for a fireside chat. The appearance may provide investor visibility, but no new business or financial information was announced. Conference announcement
- Neutral Sentiment: CEO Laura Francis and insiders Anshul Maheshwari and Michael Pisetsky sold a combined 26,959 shares, worth about $628,000. The reported sales were to cover tax withholding on vested equity awards, and the sellers retained substantial shareholdings—factors that make the transactions less indicative of a change in outlook. Insider sale report
SiBone Company Profile
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Featured Articles
- Five stocks we like better than SiBone
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
